Robeco Institutional Asset Management B.V. Increases Stock Position in Insulet Corporation $PODD

Key Points

• Robeco Institutional Asset Management increased its Insulet stake 6.7% in Q4 to 215,522 shares (about $61.26 million), representing roughly 0.31% of the company.
• Insulet director Michael R. Minogue bought 2,030 shares at $246.23 on Feb. 25, raising his holdings to 17,483 shares (a 13.14% increase), indicating insider buying.
• While the sell‑side consensus remains a “Moderate Buy” with an average target of $342, several analysts have cut price targets and downgraded the stock; Insulet has hit 52‑week lows, short interest rose to ~4.4% of float, and a Pomerantz investor investigation adds potential downside risk.

Robeco Institutional Asset Management B.V. boosted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 215,522 shares of the medical instruments supplier's stock after acquiring an additional 13,508 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.31% of Insulet worth $61,260,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Trilogy Capital Inc. increased its stake in Insulet by 33.6% in the fourth quarter. Trilogy Capital Inc. now owns 12,457 shares of the medical instruments supplier's stock valued at $3,541,000 after purchasing an additional 3,136 shares during the period. V Square Quantitative Management LLC acquired a new position in Insulet during the fourth quarter worth about $581,000. OFI Invest Asset Management acquired a new position in Insulet during the fourth quarter worth about $134,000. Ledyard National Bank acquired a new position in Insulet during the fourth quarter worth about $349,000. Finally, Prime Capital Investment Advisors LLC lifted its holdings in shares of Insulet by 10.1% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 902 shares of the medical instruments supplier's stock valued at $256,000 after purchasing an additional 83 shares in the last quarter.

Insiders Place Their Bets

In other news, Director Michael R. Minogue acquired 2,030 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.39% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on PODD shares. Oppenheimer reduced their price objective on shares of Insulet from $365.00 to $300.00 and set an "outperform" rating on the stock in a research note on Thursday, February 19th. Evercore dropped their price target on shares of Insulet from $340.00 to $240.00 and set an "outperform" rating for the company in a research report on Monday, April 6th. Sanford C. Bernstein cut their target price on shares of Insulet from $380.00 to $330.00 and set an "outperform" rating on the stock in a research note on Thursday, February 19th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Insulet in a report on Thursday, January 22nd. Finally, Truist Financial lowered their price target on shares of Insulet from $390.00 to $360.00 and set a "buy" rating for the company in a report on Thursday, February 19th. Nineteen analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average price target of $342.00.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet named Mike Panos to lead Omnipod commercial execution and growth, a hire that could help accelerate sales execution and product rollout if he delivers on execution targets. Insulet Taps Mike Panos To Drive Omnipod Commercial Execution And Growth
• Positive Sentiment: Some analysts still see large upside (one article cites ~75% upside), suggesting valuation and longer-term growth expectations remain attractive to parts of the sell-side despite recent weakness. Analysts See 75% Upside on Insulet Corporation (PODD) Despite Weak Share Price Momentum
• Neutral Sentiment: Recent writeups examine Insulet’s valuation after the share-price pullback; these provide context for whether current levels offer a buying opportunity versus downside risk. A Look At Insulet (PODD) Valuation After Recent Share Price Weakness
• Neutral Sentiment: The April 10 short-interest data feed shows inconsistent/zero values (likely a reporting error) — treat that specific print cautiously while focusing on the more reliable March figures below.
• Negative Sentiment: Short interest rose in late March to ~3.05M shares (about 4.4% of float), increasing the short-interest ratio to ~3.5 days — higher short interest can amplify downward pressure and volatility.
• Negative Sentiment: Citigroup downgraded PODD to Neutral, and Evercore cut its price target to $240 — analyst downgrades and lower targets are primary drivers of selling pressure. Citigroup Downgrades Insulet NASDAQ: PODD to Neutral Evercore Cuts Insulet NASDAQ: PODD Price Target to $240.00
• Negative Sentiment: Multiple headlines note that PODD has hit new 52-week/12-month lows after analyst actions, signaling bearish momentum and potential stop-loss triggers for some holders. Insulet NASDAQ: PODD Hits New 12-Month Low on Analyst Downgrade Insulet Corp. stock falls to new 52-week low
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Insulet, introducing potential litigation risk and an additional overhang for the stock until resolved. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODD

Insulet Stock Performance

NASDAQ PODD opened at $196.93 on Monday. Insulet Corporation has a one year low of $195.28 and a one year high of $354.88. The company has a 50-day simple moving average of $232.25 and a 200-day simple moving average of $279.24. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The firm has a market capitalization of $13.64 billion, a PE ratio of 56.27, a price-to-earnings-growth ratio of 1.18 and a beta of 1.47.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. The business had revenue of $783.80 million during the quarter, compared to analyst estimates of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company's quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.15 EPS. On average, equities analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.